Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $617
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst David Phung maintains an Overweight rating on Eli Lilly (NYSE:LLY) and raises the price target from $560 to $617.
August 09, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Eli Lilly and raises the price target from $560 to $617, indicating a positive outlook for the stock.
The raised price target by Morgan Stanley indicates a positive outlook for Eli Lilly. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100